Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

ID#: NCT07252232

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: Phase 3

Recruitment Status: Recruiting

Start Date: December 15, 2025

End Date: July 10, 2030

Contact Information:
Revolution Medicines Study Director
1-844-2-REVMED
Summary: The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Eligibility:

Inclusion Criteria:

- At least 18 years old and has provided informed consent.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease.

- Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy.

- Must have completed most recent treatment within the past 12 weeks.

- Adequate organ function (bone marrow, liver, kidney, coagulation).

- Documented RAS mutation status.

- Able to take oral medications.

Exclusion Criteria:

- Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors).

- Any conditions that may affect the ability to take or absorb study drug.

- Major surgery within 28 days prior to randomization.

- Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Find a Clinical Trial Find Cancer Clinical Trials